Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive Phase 3 results that showed adding Dupixent ® (dupilumab) to standard-of-care topical corticosteroids (TCS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results